Invasive aspergillosis: new insights into disease, diagnostic and treatment
- PMID: 23278538
- DOI: 10.2174/13816128113199990330
Invasive aspergillosis: new insights into disease, diagnostic and treatment
Abstract
Aspergillus infections are a threat to in patients with hematological malignancies. Known risk factors are profound and long lasting neutropenia, uncontrolled graft versus host disease, continuous administration of steroids and environmental factors such as hospital construction. Numerous efforts have been undertaken for prophylaxis of invasive aspergillosis in high-risk populations. Most of them failed to demonstrate survival advantages. Prophylaxis makes sense, since diagnosis and treatment of invasive aspergillosis remain difficult. The introduction of non-culture based tools for the diagnosis of invasive aspergillosis is an important step forward for early and sensitive diagnosis of invasive aspergillosis. Early treatment is the cornerstone of a successful management of invasive aspergillosis. Substantial improvement came with the introduction of lipid formulations of amphotericin B in the early 1990s. Voriconazole was the first azole that improved the overall survival for patients with invasive aspergillosis. Newer azoles and the echinocandins were introduced for the treatment of invasive aspergillosis in the late 1990s. Voriconazole and liposomal amphotericin B allow a safer and more effective treatment of invasive aspergillosis when compared with amphotericin B-desoxycholate. Combination of antifungal agents has been introduced in clinical trials. Up to now no significant benefit has been obtained with antifungal combination compared to voriconazole alone. Because mortality of invasive aspergillosis remains up to more than 50%, prophylaxis, early diagnosis and early initiation of antifungal therapy are of utmost importance for the reduction of invasive aspergillosis related mortality. Despite all advances in the management of invasive aspergillosis important questions remain unresolved. This article reviews the current state and new insights in the management of invasive aspergillosis and points out clinicians unmet needs.
Similar articles
-
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.Eur J Med Res. 2011 Apr 28;16(4):145-52. doi: 10.1186/2047-783x-16-4-145. Eur J Med Res. 2011. PMID: 21486728 Free PMC article. Review.
-
[Guideline based treatment of invasive aspergillosis].Mycoses. 2010 May;53 Suppl 1:36-43. doi: 10.1111/j.1439-0507.2009.01840.x. Mycoses. 2010. PMID: 20433655 German.
-
Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.Drugs. 2007;67(11):1567-601. doi: 10.2165/00003495-200767110-00004. Drugs. 2007. PMID: 17661528 Review.
-
[Invasive Aspergillosis in Hematological Patients].Med Mycol J. 2016;57(2):J77-88. doi: 10.3314/mmj.57.J77. Med Mycol J. 2016. PMID: 27251320 Review. Japanese.
-
Treatment of drug-resistant Aspergillus infection.Expert Opin Pharmacother. 2015;16(15):2267-70. doi: 10.1517/14656566.2015.1083976. Epub 2015 Sep 2. Expert Opin Pharmacother. 2015. PMID: 26328502
Cited by
-
Invasive pulmonary aspergillosis among patients with severe community-acquired pneumonia and influenza in ICUs: a retrospective cohort study.Pneumonia (Nathan). 2024 May 25;16(1):10. doi: 10.1186/s41479-024-00129-9. Pneumonia (Nathan). 2024. PMID: 38790032 Free PMC article.
-
Co-infection of Nocardia and Aspergillus fumigatus in a immunosuppressed patient: Case report.Medicine (Baltimore). 2024 Jan 26;103(4):e37073. doi: 10.1097/MD.0000000000037073. Medicine (Baltimore). 2024. PMID: 38277515 Free PMC article.
-
Transcriptomics-based investigation of molecular mechanisms underlying synergistic antimicrobial effects of AgNPs and Domiphen on the human fungal pathogen Aspergillus fumigatus.Front Microbiol. 2023 Feb 1;14:1089267. doi: 10.3389/fmicb.2023.1089267. eCollection 2023. Front Microbiol. 2023. PMID: 36819018 Free PMC article.
-
The C2H2 Transcription Factor SltA Contributes to Azole Resistance by Coregulating the Expression of the Drug Target Erg11A and the Drug Efflux Pump Mdr1 in Aspergillus fumigatus.Antimicrob Agents Chemother. 2021 Mar 18;65(4):e01839-20. doi: 10.1128/AAC.01839-20. Print 2021 Mar 18. Antimicrob Agents Chemother. 2021. PMID: 33431412 Free PMC article.
-
Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study.BMC Pulm Med. 2020 Sep 9;20(1):239. doi: 10.1186/s12890-020-01257-w. BMC Pulm Med. 2020. PMID: 32907585 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
